FIELD: chemistry.
SUBSTANCE: invention relates to a method of treating one or more drug dependences, nicotine addiction and/or obesity, involving administration of an effective amount of the compound, sufficient for lowering production and/or secretion of dopamine, where the said compound has general formula: 
or its pharmaceutically acceptable salts, where R1 is hydrogen or methyl when R2 is Cy; R2 is hydrogen or methyl when R1 is Cy; and where Cy is a 
group which is optionally substituted with -R, -OR, -NR2 or a halogen, where each R is independently optionally substituted with a lower alkyl, aryl or heteroaryl. The invention also relates to methods of treating one or more drug dependences, nicotine addiction or obesity.
EFFECT: novel methods of treating addictions.
5 cl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SPIRO CONDENSED PYRROLIDINE DERIVATIVES AS INHIBITORS OF DEUBIQUITINATING ENZYMES (DUB) | 2017 |
|
RU2730552C2 |
| OXADIAZOLES AS MUSCARINIC RECEPTOR AGONISTS M AND/OR M | 2019 |
|
RU2817018C2 |
| 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3,5]NONANE DERIVATIVES AND USE THEREOF AS GHRELIN RECEPTOR ANTAGONISTS OR INVERSE AGONISTS | 2011 |
|
RU2524341C2 |
| MENIN-MLL INTERACTION INHIBITORS | 2017 |
|
RU2799820C2 |
| METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
| HETEROCYCLIC COMPOUNDS | 2019 |
|
RU2809257C2 |
| NEW ISOXAZOLIL ETHER DERIVATIVES AS PAM GABA A ALFA5 | 2019 |
|
RU2800160C2 |
| 2-OXA-5-AZABICYCLO[2.2.1]HEPTANE-3-YL DERIVATIVES | 2015 |
|
RU2697651C2 |
| PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2017 |
|
RU2796400C2 |
| NEW BIPHENYL COMPOUND OR ITS SALT | 2018 |
|
RU2765152C2 |
